Intellia Therapeutics, Inc. revenue for the last year amounted to 36.27 M USD, the most of which — 36.27 M USD — came from its highest performing source at the moment, Genome Editing-based Therapies, the year earlier bringing 52.12 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Intellia Therapeutics, Inc. 36.27 M USD, and the year before that — 52.12 M USD.